Want to see SE:ACE full AI Analyst Report?
ACE Stock Chart & Stats
kr3.17
-kr0.11(-3.47%)
At close: 4:00 PM EST
kr3.17
-kr0.11(-3.47%)
Day’s Range― - ―
52-Week Rangekr2.53 - kr5.23
Previous CloseN/A
Volume171.87K
Average Volume (3M)1.75M
Market Cap
kr438.00M
Enterprise Valuekr371.41M
Total Cash (Recent Filing)kr33.89M
Total Debt (Recent Filing)kr689.00K
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding133,535,460
10 Day Avg. Volume1,883,755
30 Day Avg. Volume1,753,338
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.67
Price to Sales (P/S)0.00
P/FCF Ratio-5.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.26
Revenue Forecast (FY)kr87.22M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Stronger Balance SheetExtremely low debt reduces insolvency and interest burden risk, giving management flexibility to fund development via equity or non-debt financing. Over a 2–6 month horizon, low leverage materially lowers near-term bankruptcy risk and preserves strategic optionality for partnerships or licensing.
Improving Cash Burn Trend Versus Prior YearsA materially improved burn profile indicates operational discipline and potential cost-base optimization, which can extend runway and reduce near-term financing needs. If sustained, this trend supports longer-term program continuity and increases the chance of reaching clinical or regulatory inflection points.
Focused Product Candidate Addressing A Structural Diagnostic NeedA single, clearly defined lead asset targeting patients unsuitable for gadolinium-based contrast agents offers a focused go-to-market path and differentiated clinical niche. This concentration can simplify trial design, regulatory strategy, and partnership discussions, benefiting long-term commercialization prospects.
Bears Say
No Revenue And Persistent Large LossesAbsence of any revenue and sustained multi-year net losses mean the company lacks internal cash generation to fund operations. Over months, this structural deficit forces reliance on external financing, increasing dilution risk and constraining long-term strategic execution without partner deals or successful commercialization.
Consistently Negative Operating And Free Cash FlowPersistently negative operating and free cash flows show the business consumes cash to sustain R&D and operations. This structural cash burn heightens runway pressure, raises likelihood of frequent financing rounds, and can limit investment in pivotal trials or commercialization efforts over the medium term.
Small Team And Development-stage Execution RiskA very small headcount implies constrained in-house capacity for clinical development, regulatory, and commercial preparation. Sustained progress typically requires expanded capabilities or partners; without them, execution timelines and quality risk lengthen, increasing dependence on external collaborations or hires.
Ascelia Pharma AB News
ACE FAQ
What was Ascelia Pharma AB’s price range in the past 12 months?
Ascelia Pharma AB lowest stock price was kr2.53 and its highest was kr5.23 in the past 12 months.
What is Ascelia Pharma AB’s market cap?
Ascelia Pharma AB’s market cap is kr438.00M.
When is Ascelia Pharma AB’s upcoming earnings report date?
Ascelia Pharma AB’s upcoming earnings report date is Aug 20, 2026 which is in 48 days.
How were Ascelia Pharma AB’s earnings last quarter?
Ascelia Pharma AB released its earnings results on May 12, 2026. The company reported -kr0.129 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.129.
Is Ascelia Pharma AB overvalued?
According to Wall Street analysts Ascelia Pharma AB’s price is currently Overvalued.
Does Ascelia Pharma AB pay dividends?
Ascelia Pharma AB does not currently pay dividends.
What is Ascelia Pharma AB’s EPS estimate?
Ascelia Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ascelia Pharma AB have?
Ascelia Pharma AB has 133,535,460 shares outstanding.
What happened to Ascelia Pharma AB’s price movement after its last earnings report?
Ascelia Pharma AB reported an EPS of -kr0.129 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.372%.
Which hedge fund is a major shareholder of Ascelia Pharma AB?
Currently, no hedge funds are holding shares in SE:ACE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ascelia Pharma AB
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trials for magnetic resonance imaging (MRI) of the liver. Furthermore, it is advancing Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 development for gastric cancer therapy. Ascelia Pharma has also entered into a clinical collaboration agreement with Taiho Oncology, Inc. to develop Oncoral in combination with LONSURF. The company was established in 2000 and has its headquarters situated in Malmö, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Isofol Medical AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Cantargia AB
―